Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Durvalumab”

720 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 720 results

Testing effectiveness (Phase 2)Looking for participantsNCT06728410
What this trial is testing

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Who this might be right for
Intrahepatic CholangiocarcinomaFGFR2 Gene RearrangementFGFR2 Gene Mutation
Mehmet Akce 38
Large-scale testing (Phase 3)Study completedNCT04449861
What this trial is testing

Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)

Who this might be right for
Small Cell Lung Carcinoma Extensive Disease
AstraZeneca 166
Early research (Phase 1)WithdrawnNCT03196401
What this trial is testing

Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone Plasmacytoma

Who this might be right for
Solitary Bone Plasmacytoma
Memorial Sloan Kettering Cancer Center
Large-scale testing (Phase 3)Ended earlyNCT04866017
What this trial is testing

Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
BeiGene 63
Testing effectiveness (Phase 2)Ended earlyNCT03075527
What this trial is testing

Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma

Who this might be right for
Mesothelioma
Dana-Farber Cancer Institute 19
Testing effectiveness (Phase 2)Active Not RecruitingNCT03875573
What this trial is testing

Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:

Who this might be right for
Luminal B
Jules Bordet Institute 147
Early research (Phase 1)Ended earlyNCT03665129
What this trial is testing

IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Innate Pharma 73
Testing effectiveness (Phase 2)WithdrawnNCT04889066
What this trial is testing

Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases

Who this might be right for
Brain Metastases from Non-small Cell Lung Cancer
University of Texas Southwestern Medical Center
Testing effectiveness (Phase 2)Looking for participantsNCT03539822
What this trial is testing

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

Who this might be right for
Gastric CancerEsophageal AdenocarcinomaHepatocellular Carcinoma+1 more
Anwaar Saeed 117
Large-scale testing (Phase 3)Study completedNCT02551159
What this trial is testing

Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer

Who this might be right for
Squamous Cell Carcinoma of the Head and Neck
AstraZeneca 823
Early research (Phase 1)UnknownNCT03799744
What this trial is testing

Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma

Who this might be right for
Head and Neck NeoplasmsCarcinoma, Squamous Cell of Head and NeckMetastasis+1 more
Institut Català d'Oncologia 20
Testing effectiveness (Phase 2)Looking for participantsNCT03907475
What this trial is testing

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

Who this might be right for
Locally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm
National Cancer Institute (NCI) 115
Early research (Phase 1)Study completedNCT01938612
What this trial is testing

A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours

Who this might be right for
Advanced Solid Tumors
AstraZeneca 269
Testing effectiveness (Phase 2)Looking for participantsNCT05742607
What this trial is testing

IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

Who this might be right for
Non Small Cell Lung Cancer
Innate Pharma 70
Testing effectiveness (Phase 2)Study completedNCT03430895
What this trial is testing

Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract

Who this might be right for
Non-Transitional Cell Carcinoma of the Urothelial TractSmall Cell of the BladderAdenocarcinoma of the Bladder+2 more
Memorial Sloan Kettering Cancer Center 15
Large-scale testing (Phase 3)Looking for participantsNCT06992609
What this trial is testing

Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.

Who this might be right for
Small Cell Lung Carcinoma
AstraZeneca 70
Testing effectiveness (Phase 2)Study completedNCT03167619
What this trial is testing

Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)

Who this might be right for
Triple Negative Breast Cancer
Duke University 45
Testing effectiveness (Phase 2)Looking for participantsNCT03694236
What this trial is testing

Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC

Who this might be right for
Potentially Resectable Stage II/IIIa NSCLC
Yonsei University 39
Testing effectiveness (Phase 2)Looking for participantsNCT06393816
What this trial is testing

FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum

Who this might be right for
Large Cell Neuroendocrine Carcinoma of the Lung
Centre Leon Berard 80
Very early researchWithdrawnNCT04088032
What this trial is testing

Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer

Who this might be right for
Breast Cancer FemaleLocally Advanced Breast CancerHormone Receptor Positive Malignant Neoplasm of Breast
Alison Stopeck
Load More Results